비교리스트

 카트 문의
시장보고서
상품코드
1193044

간질환 진단 시장 : 기술별(영상 진단, 실험실 검사, 내시경 검사, 생검), 최종 사용자별(병원, 연구소, 기타) - 세계 기회 분석 및 산업 예측(2021-2031년)

Liver Disease Diagnostics Market By Technique (imaging, laboratory tests, endoscopy, biopsy), By End Use (hospitals, laboratories, others): Global Opportunity Analysis and Industry Forecast, 2021-2031
발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 203 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

간 질환 진단 시장은 2021년에 345억 2,040만 달러가 되고, 2031년에는 619억 6,210만 달러에 이르렀으며, 2022년부터 2031년에 걸쳐 CAGR 6.1%로 성장할 것으로 예측됩니다.

간은 신체의 중요한 장기이며 빌리루빈, 콜레스테롤, 호르몬, 약물로 배설하는 담즙의 생성 및 배설 등 500개 이상의 기능과 주요 기능을 가지고 있습니다. 감염과 싸우고 독소를 제거하고 혈액을 정화하는 데 도움이됩니다. 간 질환은 간에 영향을 미치는 다양한 복잡한 증상으로 구성됩니다. 간 기능 장애는 치명적이며, A형 간염, B형 간염, C형 간염, 비알코올성 지방성 간 질환, 간암, 담관암, 간세포 선종, 간경변 등 다양한 급성 및 만성 질환을 일으킬 수 있습니다. 간 질환의 원인은 감염증(기생충, 바이러스), 만성 알코올 중독, 간에 지방 축적, 면역계의 이상, 유전(헤모크로마토시스, 고옥시뇨, 윌슨병) 등이 있습니다.

간 질환 진단에는 화상 진단, 임상 검사, 내시경 검사, 생검 등 다양한 방법이 이용됩니다. 간질환의 진단에 MRI, CT스캔, 검사실 등의 영상진단의 이용이 증가하고 간질환진단 시장의 성장을 뒷받침하고 있습니다.

간 질환 진단 시장의 성장을 촉진하는 주요 요인으로는 기술적 진보의 상승, 간염, B형 만성 간염, C형 만성 간염, 비알코올성 지방성 간 질환(NAFLD) 등의 만성 간 질환 병률의 상승 등을 들 수 있습니다. 또한 기타 간 질환으로는 침윤성 간 질환(간성 유육종증, 아밀로이드증 등), α-1 안티트립신 결손증, 원발성 담즙성 담관염, 원발성 경화성 담관염 등을 들 수 있습니다.

예를 들어, 2022년 6월에 발표된 세계보건기구(WHO) 보고서에 따르면, 세계에서는 추정 5800만명이 C형 만성 간염 바이러스에 감염되고 있으며 연간 약 150만명이 새롭게 감염 그렇습니다. 또, 청년·소아에서는 추정 320만명이 C형 만성 간염에 감염되고 있습니다고 되어 있습니다. 이러한 요인은 간질환 진단제의 수요를 높이고 있습니다.

그러나 불리한 진료보상, 훈련받은 의사와 내시경의 부족, 생검 부작용, 간질환 진단제와 관련된 고비용 등의 합병증이 시장 성장을 방해할 것으로 예상됩니다. 한편, 개발도상국의 암메트 메디컬 수요와 신흥국의 유리한 비즈니스 기회는 앞으로 전세계 간 질환 진단제 제조업체에게 큰 비즈니스 기회를 가져올 것으로 예상됩니다.

또한 만성 간질환, 간염, 간암 유병률 상승, 신약 개발에 있어서 연구개발 투자 증가, 간질환 저침습 진단법에 대한 인지도 상승으로 건강 관리 사업 성장이 예측됨 합니다. 이 때문에 예측기간 동안 주요 기업이 이 시장에 투자함으로써 유익한 기회를 제공할 수 있을 것으로 예상됩니다.

목차

제1장 소개

제2장 주요 요약

제3장 시장 개요

  • 시장의 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 촉진 요인
    • 억제 요인
    • 기회
  • COVID-19 영향 분석

제4장 간질환 진단약 시장 : 기술별

  • 개요
    • 시장 규모·예측
  • 이미징
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 실험실 테스트
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 내시경 검사
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 생검
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제5장 간질환 진단약 시장 : 최종 사용자별

  • 개요
    • 시장 규모 및 예측
  • 병원
    • 주요 시장 동향 · 성장 요인 · 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 실험실
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 요인, 기회
    • 시장 규모·예측 : 지역별
    • 시장 분석 : 국가별

제6장 간질환 진단약 시장 : 지역별

  • 개요
    • 시장 규모 및 예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모·예측 : 기술별
    • 북미 시장 규모·예측 : 최종 사용자별
    • 북미 시장 규모·예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽의 시장 규모·예측 : 기술별
    • 유럽 시장 규모·예측 : 최종 사용자별
    • 유럽 시장 규모·예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양의 시장 규모와 예측 : 기법별
    • 아시아태평양의 시장 규모·예측 : 최종 사용자별
    • 아시아태평양의 시장 규모·예측 : 국가별
      • 중국
      • 일본
      • 인도
      • 한국
      • 호주
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA의 시장 규모·예측 : 기법별
    • LAMEA의 시장 규모·예측 : 엔드유저별
    • LAMEA의 시장 규모·예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카 공화국
      • 기타 LAMEA 지역

제7장 기업 정세

  • 소개
  • 주요 성공 전략
  • 주요 10개사의 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 발전

제8장 기업 프로필

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc.
  • Cosara Diagnostics Pvt Ltd
  • Echosens
  • Meril Life Sciences Pvt. Ltd.
  • PerkinElmer
  • Qiagen NV
  • Siemen's AG
  • Thermo Fisher Scientific Inc.
  • Trivitron Healthcare
ksm 23.03.27

The liver disease diagnostics market was valued at $34,520.4 million in 2021 and is estimated to reach $61,962.1 million by 2031, growing at a CAGR of 6.1% from 2022 to 2031. 

The liver is a vital organ of the body and has more than 500 functions and primary functions such as bile production & excretion, as excretion as bilirubin, cholesterol, hormones, and drugs. It fights infection, eliminates toxins, and helps in blood purification. Liver disease comprises a range of complex conditions that affect the liver. Liver dysfunction can be fatal and can cause a variety of acute and chronic disorders, including hepatitis A, hepatitis B, hepatitis C, non-alcoholic fatty liver disease, liver cancer, bile duct cancer, liver cell adenoma, and liver cirrhosis. Liver diseases are caused due to infection (parasites and viruses), chronic alcohol abuse, fat accumulation in the liver, immune system abnormality, and inheritance (hemochromatosis, hyperoxaluria, and Wilson's disease)

Various techniques are used for the diagnosis of liver diseases such as imaging, laboratory tests, endoscopy, and biopsy. An increase in the use of imaging such as MRI, CT scan, and laboratory for the diagnosis of liver diseases boosts the growth of the liver disease diagnostics market.

Major factors that drive the growth of the liver disease diagnostics market include a rise in technological advancements, and an increase in the prevalence rate of chronic liver diseases such as hepatitis, chronic hepatitis B, chronic hepatitis C, and nonalcohol-related fatty liver disease (NAFLD). In addition, other liver diseases include infiltrative liver disorders (e.g., hepatic sarcoidosis and amyloidosis), alpha-1 antitrypsin deficiency, primary biliary cholangitis, and primary sclerosing cholangitis.

For instance, according to a report by the World Health Organization (WHO) published on June 2022, globally, an estimated 58 million people had chronic hepatitis C virus infection, with around 1.5 million new infections occurring per year. An estimated 3.2 million adolescents and children have chronic hepatitis C infection. Hence, such factors increase the demand for liver disease diagnostics.

However, unfavorable reimbursements, as well as complications such as the dearth of trained physicians & endoscopists, side effects of biopsy, and high costs associated with liver disease diagnostic products, are expected to hamper the market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for liver disease diagnostics manufacturers worldwide in the future.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in the prevalence of chronic liver diseases, hepatitis, and liver cancer; an increase in R&D investments in drug discovery & development, and a rise in awareness regarding the minimally invasive diagnostic procedure for liver diseases. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The liver disease diagnostics market is segmented on the basis of technique, end user, and region. On the basis of technique, the market is classified into imaging, laboratory tests, endoscopy, and biopsy. Depending on the end user, it is fragmented into hospitals, laboratories, and others. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Major players profiled in the report are Abbott Laboratories, Bio-Rad Laboratories Inc., Cosara Diagnostics Pvt Ltd, Echosens, Fujifilm Holdings Corporation, Meril Life Sciences Pvt. Ltd., Qiagen N.V., Siemens AG, Thermo Fisher Scientific Inc., and Trivitron Healthcare.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the liver disease diagnostics market analysis from 2021 to 2031 to identify the prevailing liver disease diagnostics market opportunities.

Market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the liver disease diagnostics market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global liver disease diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Technique

  • endoscopy
  • biopsy
  • imaging
  • laboratory tests

By End Use

  • hospitals
  • laboratories
  • others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Abbott Laboratories
    • Bio-Rad Laboratories Inc.
    • Cosara Diagnostics Pvt Ltd
    • Echosens
    • Meril Life Sciences Pvt. Ltd.
    • PerkinElmer
    • Qiagen N.V.
    • Siemen's AG
    • Thermo Fisher Scientific Inc.
    • Trivitron Healthcare

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: LIVER DISEASE DIAGNOSTICS MARKET, BY TECHNIQUE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 imaging
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 laboratory tests
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 endoscopy
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 biopsy
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: LIVER DISEASE DIAGNOSTICS MARKET, BY END USE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 hospitals
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 laboratories
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country
  • 5.4 others
    • 5.4.1 Key market trends, growth factors and opportunities
    • 5.4.2 Market size and forecast, by region
    • 5.4.3 Market analysis by country

CHAPTER 6: LIVER DISEASE DIAGNOSTICS MARKET, BY REGION

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 North America
    • 6.2.1 Key trends and opportunities
    • 6.2.2 North America Market size and forecast, by Technique
    • 6.2.3 North America Market size and forecast, by End Use
    • 6.2.4 North America Market size and forecast, by country
      • 6.2.4.1 U.S.
      • 6.2.4.1.1 Market size and forecast, by Technique
      • 6.2.4.1.2 Market size and forecast, by End Use
      • 6.2.4.2 Canada
      • 6.2.4.2.1 Market size and forecast, by Technique
      • 6.2.4.2.2 Market size and forecast, by End Use
      • 6.2.4.3 Mexico
      • 6.2.4.3.1 Market size and forecast, by Technique
      • 6.2.4.3.2 Market size and forecast, by End Use
  • 6.3 Europe
    • 6.3.1 Key trends and opportunities
    • 6.3.2 Europe Market size and forecast, by Technique
    • 6.3.3 Europe Market size and forecast, by End Use
    • 6.3.4 Europe Market size and forecast, by country
      • 6.3.4.1 Germany
      • 6.3.4.1.1 Market size and forecast, by Technique
      • 6.3.4.1.2 Market size and forecast, by End Use
      • 6.3.4.2 France
      • 6.3.4.2.1 Market size and forecast, by Technique
      • 6.3.4.2.2 Market size and forecast, by End Use
      • 6.3.4.3 UK
      • 6.3.4.3.1 Market size and forecast, by Technique
      • 6.3.4.3.2 Market size and forecast, by End Use
      • 6.3.4.4 Italy
      • 6.3.4.4.1 Market size and forecast, by Technique
      • 6.3.4.4.2 Market size and forecast, by End Use
      • 6.3.4.5 Spain
      • 6.3.4.5.1 Market size and forecast, by Technique
      • 6.3.4.5.2 Market size and forecast, by End Use
      • 6.3.4.6 Rest of Europe
      • 6.3.4.6.1 Market size and forecast, by Technique
      • 6.3.4.6.2 Market size and forecast, by End Use
  • 6.4 Asia-Pacific
    • 6.4.1 Key trends and opportunities
    • 6.4.2 Asia-Pacific Market size and forecast, by Technique
    • 6.4.3 Asia-Pacific Market size and forecast, by End Use
    • 6.4.4 Asia-Pacific Market size and forecast, by country
      • 6.4.4.1 China
      • 6.4.4.1.1 Market size and forecast, by Technique
      • 6.4.4.1.2 Market size and forecast, by End Use
      • 6.4.4.2 Japan
      • 6.4.4.2.1 Market size and forecast, by Technique
      • 6.4.4.2.2 Market size and forecast, by End Use
      • 6.4.4.3 India
      • 6.4.4.3.1 Market size and forecast, by Technique
      • 6.4.4.3.2 Market size and forecast, by End Use
      • 6.4.4.4 South Korea
      • 6.4.4.4.1 Market size and forecast, by Technique
      • 6.4.4.4.2 Market size and forecast, by End Use
      • 6.4.4.5 Australia
      • 6.4.4.5.1 Market size and forecast, by Technique
      • 6.4.4.5.2 Market size and forecast, by End Use
      • 6.4.4.6 Rest of Asia-Pacific
      • 6.4.4.6.1 Market size and forecast, by Technique
      • 6.4.4.6.2 Market size and forecast, by End Use
  • 6.5 LAMEA
    • 6.5.1 Key trends and opportunities
    • 6.5.2 LAMEA Market size and forecast, by Technique
    • 6.5.3 LAMEA Market size and forecast, by End Use
    • 6.5.4 LAMEA Market size and forecast, by country
      • 6.5.4.1 Brazil
      • 6.5.4.1.1 Market size and forecast, by Technique
      • 6.5.4.1.2 Market size and forecast, by End Use
      • 6.5.4.2 Saudi Arabia
      • 6.5.4.2.1 Market size and forecast, by Technique
      • 6.5.4.2.2 Market size and forecast, by End Use
      • 6.5.4.3 South Africa
      • 6.5.4.3.1 Market size and forecast, by Technique
      • 6.5.4.3.2 Market size and forecast, by End Use
      • 6.5.4.4 Rest of LAMEA
      • 6.5.4.4.1 Market size and forecast, by Technique
      • 6.5.4.4.2 Market size and forecast, by End Use

CHAPTER 7: COMPANY LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Key developments

CHAPTER 8: COMPANY PROFILES

  • 8.1 Abbott Laboratories
    • 8.1.1 Company overview
    • 8.1.2 Company snapshot
    • 8.1.3 Operating business segments
    • 8.1.4 Product portfolio
    • 8.1.5 Business performance
    • 8.1.6 Key strategic moves and developments
  • 8.2 Bio-Rad Laboratories Inc.
    • 8.2.1 Company overview
    • 8.2.2 Company snapshot
    • 8.2.3 Operating business segments
    • 8.2.4 Product portfolio
    • 8.2.5 Business performance
    • 8.2.6 Key strategic moves and developments
  • 8.3 Cosara Diagnostics Pvt Ltd
    • 8.3.1 Company overview
    • 8.3.2 Company snapshot
    • 8.3.3 Operating business segments
    • 8.3.4 Product portfolio
    • 8.3.5 Business performance
    • 8.3.6 Key strategic moves and developments
  • 8.4 Echosens
    • 8.4.1 Company overview
    • 8.4.2 Company snapshot
    • 8.4.3 Operating business segments
    • 8.4.4 Product portfolio
    • 8.4.5 Business performance
    • 8.4.6 Key strategic moves and developments
  • 8.5 Meril Life Sciences Pvt. Ltd.
    • 8.5.1 Company overview
    • 8.5.2 Company snapshot
    • 8.5.3 Operating business segments
    • 8.5.4 Product portfolio
    • 8.5.5 Business performance
    • 8.5.6 Key strategic moves and developments
  • 8.6 PerkinElmer
    • 8.6.1 Company overview
    • 8.6.2 Company snapshot
    • 8.6.3 Operating business segments
    • 8.6.4 Product portfolio
    • 8.6.5 Business performance
    • 8.6.6 Key strategic moves and developments
  • 8.7 Qiagen N.V.
    • 8.7.1 Company overview
    • 8.7.2 Company snapshot
    • 8.7.3 Operating business segments
    • 8.7.4 Product portfolio
    • 8.7.5 Business performance
    • 8.7.6 Key strategic moves and developments
  • 8.8 Siemen's AG
    • 8.8.1 Company overview
    • 8.8.2 Company snapshot
    • 8.8.3 Operating business segments
    • 8.8.4 Product portfolio
    • 8.8.5 Business performance
    • 8.8.6 Key strategic moves and developments
  • 8.9 Thermo Fisher Scientific Inc.
    • 8.9.1 Company overview
    • 8.9.2 Company snapshot
    • 8.9.3 Operating business segments
    • 8.9.4 Product portfolio
    • 8.9.5 Business performance
    • 8.9.6 Key strategic moves and developments
  • 8.10 Trivitron Healthcare
    • 8.10.1 Company overview
    • 8.10.2 Company snapshot
    • 8.10.3 Operating business segments
    • 8.10.4 Product portfolio
    • 8.10.5 Business performance
    • 8.10.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제